<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071812</url>
  </required_header>
  <id_info>
    <org_study_id>LBRA01</org_study_id>
    <nct_id>NCT00071812</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)</brief_title>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Human Genome Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of 3 different doses of
      belimumab, administered in addition to standard therapy, in patients with rheumatoid
      arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of three different doses of
      belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy,
      compared to placebo plus standard therapy in patients with RA. All patients were to be dosed
      on Days 0, 14, and 28, then every 28 days for the remainder of 24 weeks. Patients completing
      the 24-week period could enter a 24-week open-label extension; belimumab patients received
      the same dose or were switched to 10 mg/kg at the investigator's discretion and former
      placebo patients received belimumab 10 mg/kg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With an ACR50 Response at Week 24, Based on ESR</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With an ACR70 Response at Week 24, Based on ESR</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First ACR20 Response, Based on ESR</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First ACR50 Response, Based on ESR</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First ACR70 Response, Based on ESR</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Disease Activity Score 28 (DAS28) at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (&gt;5.1=active disease; &lt;3.2=well controlled disease; &lt;2.6=remission). Change from baseline &gt;1.2 = good response and ≤0.6 = non-response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First DAS28 Response</measure>
    <time_frame>0 to 24 weeks</time_frame>
    <description>DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a &quot;good&quot; or a &quot;moderate&quot; improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as &gt;1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and &gt; 0.6 with a DAS28 score of &gt; 5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Modified Total Sharp Score at Week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE) Overview</measure>
    <time_frame>Up to 56 weeks</time_frame>
    <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Placebo plus SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 1 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 4 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 10 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.</description>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 1 mg/kg</intervention_name>
    <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 1 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 4 mg/kg</intervention_name>
    <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 4 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 10 mg/kg</intervention_name>
    <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 10 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Diagnosis of RA for at least 1 year

          -  Failed at least 1 disease modifying anti-rheumatic drug (DMARD) due to toxicity or
             lack of efficacy. These drugs must include 1 or more of the following: methotrexate,
             parenteral gold, sulfasalazine, leflunomide, and tumor necrosis factor-alpha (TNFα)
             inhibitors (infliximab, etanercept or adalimumab)

          -  Active RA disease of at least moderate disease activity

          -  Be on a stable RA treatment regimen for at least the past 60 days (for DMARDS); if on
             non-steroidal anti-inflammatory drugs (NSAIDs) or steroids these must be at a stable
             dose for the last 30 days

        Primary Exclusion Criteria:

          -  Received a non-FDA approved investigational agent within the last 28 days

          -  Currently receiving or received within the last 60 days the following: TNFα-inhibitors
             (infliximab, etanercept, adalimumab) or interleukin-1 receptor antagonist (anakinra)

          -  Currently receiving or received within the last 6 months the following: anti-CD20
             antibody (rituximab) or cyclophosphamide

          -  Steroid injection into any joint within the last 30 days

          -  History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency

          -  History of chronic infection that has been active within last 6 months, or herpes
             zoster within last 90 days, or any infection requiring hospitalization or intravenous
             medication within last 60 days

          -  Human immunodeficiency virus (HIV), Hepatitis-B, Hepatitis-C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis Research</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wallace Rheumatic Disease Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boling Clinical Trials</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCDMC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-1418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care Center, Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126-1650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates &amp; Osteoporosis Center Of Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Central Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis and Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Clinic</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Specialists</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Center for Better Bone and Joint Health</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Osteoporosis and Arthritis Clinical Trial Center</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Rhematology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Nebraska</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Center</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strafford Medical Associates, P.A.</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Rheumatology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY-Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic and Carolina Bone and Joint</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBride Clinic</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center For Arthritis Therapy &amp; Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine &amp; ASPH</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Centers of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Research Center</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Diseases Clinic</name>
      <address>
        <city>Weber</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Northern Virginia, P.C.</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmonds Rheumatology Associates</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026-8047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Clinical Reserach</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026-8047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Northwest Clinical Trials</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Center</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, Ltd.</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin , Inc</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Research Foundation</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2003</study_first_submitted>
  <study_first_submitted_qc>November 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2003</study_first_posted>
  <results_first_submitted>February 27, 2012</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2012</results_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study.</description>
        </group>
        <group group_id="P2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study. The 24-week open-label extension period of the study included patients who completed the 24-week double-blind period and opted to continue to receive the same dose in the 24-week open-label extension period of the study.</description>
        </group>
        <group group_id="P3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study. The 24-week open-label extension period of the study included patients who completed the 24-week double-blind period and opted to continue to receive the same dose in the 24-week open-label extension period of the study.</description>
        </group>
        <group group_id="P4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study. The 24 week-open label extension period of the study included patients who completed the 24-week double-blind period and opted to continue in the 24-week open-label period of the study and included patients who were originally randomized to the belimumab 10 mg/kg group in the double-blind period, patients who switched to belimumab 10 mg/kg at the investigator's discretion, and former placebo patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>24-Week Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-Week Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Of 59: 56 switched to 10 mg/kg; 3 elected not to continue in the open-label extension.</participants>
                <participants group_id="P2" count="11">Of 66: 53 switched to 10 mg/kg; 2 elected not continue in the open-label extension.</participants>
                <participants group_id="P3" count="8">Of 63: 53 switched to 10 mg/kg; 2 elected not continue in the open-label extension.</participants>
                <participants group_id="P4" count="218">Of 60: 56 continued with 10 mg/kg; 4 elected not to continue in the open-label extension.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="B2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="B3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="B4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="283"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="8.8"/>
                    <measurement group_id="B2" value="50.6" spread="8.3"/>
                    <measurement group_id="B3" value="50.7" spread="10.2"/>
                    <measurement group_id="B4" value="49.5" spread="9.3"/>
                    <measurement group_id="B5" value="50.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)</title>
        <description>An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a modified intention-to-treat (MITT) population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)</title>
          <description>An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
          <population>Analysis was performed on a modified intention-to-treat (MITT) population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="25.4"/>
                    <measurement group_id="O4" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>18.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>32.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1677</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>9.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>22.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0796</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>25.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With an ACR50 Response at Week 24, Based on ESR</title>
        <description>An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With an ACR50 Response at Week 24, Based on ESR</title>
          <description>An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="8.5"/>
                    <measurement group_id="O4" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2074</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3177</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0418</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>19.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With an ACR70 Response at Week 24, Based on ESR</title>
        <description>An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With an ACR70 Response at Week 24, Based on ESR</title>
          <description>An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate [ESR]).</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4299</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5393</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9769</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First ACR20 Response, Based on ESR</title>
        <description>The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.</description>
        <time_frame>0 to 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First ACR20 Response, Based on ESR</title>
          <description>The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="84">75th percentile could not be estimated because ≥40% of patients had no response</measurement>
                    <measurement group_id="O2" value="109" lower_limit="60" upper_limit="168"/>
                    <measurement group_id="O3" value="112" lower_limit="49">75th percentile could not be estimated because ≥40% of patients had no response</measurement>
                    <measurement group_id="O4" value="111" lower_limit="57">75th percentile could not be estimated because ≥40% of patients had no response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have any ACR response were censored at the last visit or exit visit, whichever occurred first. Patients who did not have an ACR response and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1752</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have any ACR response were censored at the last visit or exit visit, whichever occurred first. Patients who did not have an ACR response and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3440</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have any ACR response were censored at the last visit or exit visit, whichever occurred first. Patients who did not have an ACR response and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4308</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First ACR50 Response, Based on ESR</title>
        <description>Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.</description>
        <time_frame>0 to 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First ACR70 Response, Based on ESR</title>
        <description>Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.</description>
        <time_frame>0 to 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Disease Activity Score 28 (DAS28) at Week 24</title>
        <description>DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (&gt;5.1=active disease; &lt;3.2=well controlled disease; &lt;2.6=remission). Change from baseline &gt;1.2 = good response and ≤0.6 = non-response.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent and who had both a baseline and a Week 24 DAS28 score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Disease Activity Score 28 (DAS28) at Week 24</title>
          <description>DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (&gt;5.1=active disease; &lt;3.2=well controlled disease; &lt;2.6=remission). Change from baseline &gt;1.2 = good response and ≤0.6 = non-response.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent and who had both a baseline and a Week 24 DAS28 score.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.15"/>
                    <measurement group_id="O2" value="-1.3" spread="0.18"/>
                    <measurement group_id="O3" value="-0.9" spread="0.14"/>
                    <measurement group_id="O4" value="-1.5" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using last observation carried forward (LOCF) imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0958</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7864</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First DAS28 Response</title>
        <description>DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a “good” or a “moderate” improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as &gt;1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and &gt; 0.6 with a DAS28 score of &gt; 5.1.</description>
        <time_frame>0 to 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First DAS28 Response</title>
          <description>DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a “good” or a “moderate” improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as &gt;1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and &gt; 0.6 with a DAS28 score of &gt; 5.1.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="56" upper_limit="168"/>
                    <measurement group_id="O2" value="82" lower_limit="51" upper_limit="114"/>
                    <measurement group_id="O3" value="84" lower_limit="33" upper_limit="168"/>
                    <measurement group_id="O4" value="57" lower_limit="30" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have good or moderate improvement in DAS28 were censored at the last visit or exit visit, whichever occurred first. Patients who did not have good or moderate improvement in DAS28 and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0960</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have good or moderate improvement in DAS28 were censored at the last visit or exit visit, whichever occurred first. Patients who did not have good or moderate improvement in DAS28 and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2859</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required rescue RA medications were declared nonresponders, as were patients who dropped out or were missing Week 24 data. Patients who did not have good or moderate improvement in DAS28 were censored at the last visit or exit visit, whichever occurred first. Patients who did not have good or moderate improvement in DAS28 and discontinued from the study prior to study completion were censored at the last date on study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Modified Total Sharp Score at Week 24</title>
        <description>The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent and who had both a modified total Sharp score at baseline and at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Modified Total Sharp Score at Week 24</title>
          <description>The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent and who had both a modified total Sharp score at baseline and at Week 24.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                    <measurement group_id="O3" value="0.3" spread="0.2"/>
                    <measurement group_id="O4" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1940</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2561</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8707</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (AE) Overview</title>
        <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).</description>
        <time_frame>Up to 56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
          </group>
          <group group_id="O5">
            <title>Open-label Extension Period: All Active</title>
            <description>Includes all patients who completed the 24-week double-blind period and opted to continue in a 24-week open-label extension period. Belimumab patients received the same dose or were switched to 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg. AE onset may be during the extension phase or continuing from the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AE) Overview</title>
          <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent of patients with at least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                    <measurement group_id="O2" value="84.7"/>
                    <measurement group_id="O3" value="90.1"/>
                    <measurement group_id="O4" value="93.0"/>
                    <measurement group_id="O5" value="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with at least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="7.0"/>
                    <measurement group_id="O4" value="8.5"/>
                    <measurement group_id="O5" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with an AE resulting in death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 56 weeks</time_frame>
      <desc>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="E2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="E3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="E4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA for 24-week double-blind period of the study</description>
        </group>
        <group group_id="E5">
          <title>Open-label Extension Period: All Active</title>
          <description>Includes all patients who completed the 24-week double blind period and opted to continue in the 24-week open-label extension period. Belimumab patients received the same dose or were switched to 10 mg/kg at investigator discretion and former placebo patients received belimumab 10 mg/kg. AE onset may be during the extension phase or continuing from the double-blind period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Localised osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Obsessive-compulsive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="165" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For multi-center trials, no investigator will be authorized to publish study results from an individual center until the multi-center trial results are published. All manuscripts and abstracts must be submitted to the sponsor for review at least 30 days prior to submission for publication or for presentation at a scientific meeting. Proposed abstracts and publications will be reviewed promptly.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

